Denali Therapeutics Inc
NASDAQ:DNLI
Denali Therapeutics Inc
NASDAQ:DNLI
Price:
19.3 USD
5.41%
Market Closed
Updated:
May 14, 2024
Denali Therapeutics Inc
Interest Income Expense
|
Denali Therapeutics Inc
Interest Income Expense Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Interest Income Expense Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Interest Income Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Denali Therapeutics Inc
NASDAQ:DNLI
|
Interest Income Expense
$51.5m
|
CAGR 3-Years
78%
|
CAGR 5-Years
39%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Interest Income Expense
-$1.8B
|
CAGR 3-Years
8%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-19%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Interest Income Expense
-$757m
|
CAGR 3-Years
35%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-10%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Interest Income Expense
-$2.9B
|
CAGR 3-Years
-44%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
-16%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Interest Income Expense
$563.1m
|
CAGR 3-Years
78%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Interest Income Expense
$221.8m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
75%
|
CAGR 10-Years
N/A
|
See Also
What is Denali Therapeutics Inc's Interest Income Expense?
Interest Income Expense
51.5m
USD
51.5m
USD
Based on the financial report for Dec 31, 2023, Denali Therapeutics Inc's Interest Income Expense amounts to 51.5m USD.
What is Denali Therapeutics Inc's Interest Income Expense growth rate?
Interest Income Expense CAGR 5Y
39%
39%
Over the last year, the Interest Income Expense growth was 248%. The average annual Interest Income Expense growth rates for Denali Therapeutics Inc have been 78% over the past three years , 39% over the past five years .
You don't have any saved screeners yet
